A.O.U. Orbassano

Titolo:	Ruxolitinib Observational study in Myelofibrosis treated patiEnts in Italy - ROMEI
Patologia:	Myelofibrosis
Tipo di Studio:	Non-interventional study protocol (non-PASS)
Fase:	3
Principali criteri di inclusione:	1. Written informed consent must be obtained prior to any data collection. 2. Patients must be diagnosed with PMF according to the 2016 revised International Standard Criteria (Arber et al. 2016), or PPV MF or PET-MF (Barosi et al. 2008), irrespective of JAK2 mutation status. 3. Age ≥ 18 years (no upper age limit). 4. Patients must be naïve to treatment with ruxolitinib at the time of enrollment.
Principali criteri di esclusione:	No other inclusion/exclusion criteria exist other than the requirements stated in the Summary of Product Characteristics (SmPC). Ruxolitinib is contraindicated in women who are pregnant or breastfeeding and women of childbearing potential must use effective forms of birth control during treatment. Patients with serious ongoing infections should not begin treatment with ruxolitinib and a full blood count should be evaluated before starting treatment due to the drug's myelosuppressive effects (see the SmPC for more information).
Sede e contatti	Novartis Farma S.p.A. Largo U. Boccioni, 1 – 21040 Origgio (VA)